Lightlake Therapeutics Inc. to Present at 4th Annual OneMedForumNY 2013

Lightlake Therapeutics Inc. to Present at 4thAnnual OneMedForumNY 2013

LONDON--(BUSINESS WIRE)-- Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake"), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it will be participating in the 4th Annual OneMedForum New York taking place June 26th and June 27th, 2013 at The Metropolitan Club in New York City. Dr. Roger Crystal, Chief Executive Officer of Lightlake, is scheduled to present an update on the Company's corporate and clinical developments on Thursday, June 27th at 12:20 p.m. EDT.

Investors can access the live webcast of the Lightlake presentation by clicking on the following link:

About Lightlake Therapeutics Inc.
Lightlake Therapeutics Inc., a London-based biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative solutions to common addictions and related disorders. The Company holds patents covering the use of intranasal naloxone to treat Binge Eating Disorder ("BED") as well as patents covering addiction to drugs including cocaine, amphetamine, and MDMA. Lightlake is currently focused on advancing its treatment for BED, which has successfully completed Phase II clinical trials, and a Phase II trial is planned for the indication of Bulimia Nervosa. Lightlake is also applying its technology to develop a treatment for managing the complications of opioid drug addiction in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. For more information please visit:

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Lightlake Therapeutics Inc.
Dr. Roger Crystal, +44(0)203 617 8739
Chief Executive Officer
Investor Relations:
Porter, LeVay & Rose, Inc.
Michael J. Porter, 212-564-4700

KEYWORDS: United Kingdom United States Europe North America New York


The article Lightlake Therapeutics Inc. to Present at 4th Annual OneMedForumNY 2013 originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.